Tracey, L., Torgerson, C., Dysart, E., Fairhurst, C., Gridley, N. & Welch, C. (2022). Efficacy trial of the ParentChild+ programme (Evaluation report). Education Endowment Foundation. https://d2tic4wvo1iusb.cloudfront.net/documents/projects/Final-ParentChild.pdf?v=1687443633
Screening decision | Screening conclusion | HomVEE procedures and standards version |
---|---|---|
Passes screens | Eligible for review | Version 2 |
Rating | Design | Attrition | Baseline equivalence | Compromised randomization | Confounding factors | Valid, reliable measure(s) |
---|---|---|---|---|---|---|
Indeterminate | Randomized controlled trial | High | Indeterminate |
No | No |
Yes |
Three findings from the home learning observations received an indeterminate rating because HomVEE reviewers could not determine whether the intervention and comparison groups were equivalent on race or ethnicity, or socioeconomic status in the analyzed sample at baseline. All other findings received a low rating due to high attrition and because the study did not establish baseline equivalence of the preintervention outcomes. Findings from the British Picture Vocabulary Scale (BPVS-III), the Ages and Stages Questionnaire (ASQ-3), and the Home Learning Environment Index were ineligible for review because the data were pooled from multiple eligible children in a household, and HomVEE does not have standards to rate such findings. Some implementation and process findings were ineligible for review because they are not in one of HomVEE’s eligible outcome domains.
Manuscripts receive a rating of indeterminate whenever HomVEE reviewers lack sufficient information on one or more features of the study design that are required for the study to receive a rating of moderate or high. A rating of indeterminate is not a statement about the quality of the research or the research design.
Clinicaltrials.gov Identifier: None found. SocialScienceRegistry.org Identifier: None found. Registry of Efficacy and Effectiveness Studies Identifier: None found. Study registration was assessed by HomVEE for Clinicaltrials.gov beginning with the 2014 review, and for other registries beginning with the 2021 review.